SOURCE: UV Flu Technologies, Inc.

UV Flu Technologies, Inc.

November 30, 2010 10:15 ET

UV Flu Technologies Profiled by Lisa Springer, CFA, Equity Research Analyst and Financial Writer

CENTERVILLE, MA--(Marketwire - November 30, 2010) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company"), manufacturers of innovative air purification technology, announced today that the Company has been featured online at

The online report features the Company's innovative new air purification technology. Read an excerpt from the article below:

Urgent Health Threat from Airborne Viruses

There is an urgent health threat deadlier than the H1N1 pandemic on the rise, yet few Americans are aware of it. The threat comes from infections acquired while in the hospital. According to a recent government study, America's hospitals aren't adequately protecting patients from these potentially deadly infections. A 2009 report by the US Health and Human Services department found little progress has been made over the past decade in eliminating hospital-acquired infections and urged Congress to take action. As many as 98,000 Americans die each year from medical errors and preventable infections are a major contributor to the problem.

Media coverage of hospital-acquired infections, the swine flu pandemic and antibiotic resistant superbugs is raising consumer awareness and spurring government agencies and businesses to take action to safeguard public health. Demand for products that prevent the spread of airborne illnesses is rising exponentially. The swine flu pandemic created a $7 billion windfall for vaccine manufacturers, according to the Wall Street Journal, and a bonanza for makers of hand sanitizers, who experienced a 129% jump in shipments during last year's flu season.

This heightened awareness is also spreading to the nearly $8 billion annual market for indoor air quality products. These products improve air quality in commercial buildings, hospitals, schools and homes by removing airborne pathogens. Scientific studies show poor indoor air quality is a major reason for the spread of infectious disease. According to the Environmental Protection Agency, the air inside buildings where people spend 90% of their time now poses a greater threat than outdoor air.

Most air quality systems use a simple filter (either standard or HEPA) to trap pathogens. A relative newcomer to this market, UV Flu Technologies, Inc. (OTCBB: UVFT), has developed an innovative new air purification technology that is more effective than filtering. This technology disinfects indoor air by deactivating allergens and killing airborne pathogens, including bacteria, viruses and mold. UV Flu Technologies flagship product, the UV-400 ViraTech, uses high intensity germicidal UV radiation inside a killing chamber to trap and destroy harmful microbes. Extensive independent testing by EPA and FDA certified laboratories confirms UV Flu Technologies system captures and kills airborne bacteria and viruses at rates exceeding 99.2% on a first pass basis. The technology is so effective that UV Flu Technologies was able to secure a Class II medical listing enabling it to market its product as a medical device.

Since introducing its flagship device less than one year ago, UV Flu Technologies has sold units to multiple sports teams, hospitals, restaurants and other commercial customers. Two professional hockey teams (including the renowned Boston Bruins) and numerous college teams have installed UV-400 ViraTech units in their locker rooms. In addition, the company has installed units at two major hospitals and has units being evaluated by a large nursing home chain. Hospitality customers such as The Seagate Hotel and Spa in Delray Beach, Florida, the Boston Harbor Hotel and Boston's XV Beacon Hotel have installed UV-400 ViraTech units and one of the nation's largest 5 star hotels is evaluating the unit for its operations. Tests of units are also underway with one of the largest hotel and restaurant suppliers in the Northeast. In addition, "Clean Air for Everyone," a non-profit promoting clean air for schools and non-profits across America recently selected the UV-400 as its lead product for national rollout. 

UV Flu Technologies plans to expand its product line and distribution capabilities by... (To read the full report visit

About the Author - Lisa Springer, CFA Equity Research Analyst and Financial Writer
Lisa is an equity research analyst with nearly 20 years of investment research experience. She began her career in investment research in 1987 as part of the equity research team at Kemper Financial Services. In 1989, Lisa joined the Financial Relations Board, a large investor relations consulting firm, rising to the position of Director of Financial Analysis.

During her tenure with FRB, Lisa was a consultant to Boston Market, MGI Pharma, Devon Energy, Pall Corp., Upjohn Pharmaceutical and other Fortune 1000 companies. In 2000, Lisa joined NYSE-listed Great Lakes REIT as Director of Investor Relations, serving in that position until the REIT's 2004 acquisition by a private investment firm. Since then, Lisa has worked as a research analyst for a number of independent equity research firms and as a writer for investment newsletters and websites. Lisa earned an MBA in Finance from the University of Chicago in 1987 and has been a CFA (Chartered Financial Analyst) since 1991.

Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product has also been proven to reduce the concentration of odors and Volatile Organic Compounds in independent lab tests. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information visit:

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.


UV Flu Technologies, Inc.
John J. Lennon, President & CEO

Contact Information